Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Telecoms, Financials and Oil & Gas sectors led shares higher. At the close in NYSE, the Dow...
On the 25th of March, Orbimed Advisors sold 313 thousand Graybug Vision, Inc. (GRAY) shares for $1.9 million at an average price of $6.16 per share. Shares of Graybug Vision, Inc....
1. Cars.com (CARS) Cars.com (NYSE:CARS) broke out of a base on Wednesday. It came down from 14 to 3, and change, formed a nice base, popped, failed to go to the 50-day, backed...
1. Adverum Biotechnologies (ADVM)ADVM made a powerful move on Tuesday, above a double-top and breakaway gap, and jumped 5.27, or 38%, to 19.00, after reaching a multi-week and...
One stock that might be an intriguing choice for investors right now is Adverum Biotechnologies, Inc. (NASDAQ:ADVM) . This is because this security in the Medical - Biomedical and...
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company, which targets unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The Company's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.